Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06158490
PHASE2

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

Sponsor: Guangzhou JOYO Pharma Co., Ltd

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are: * The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis. * The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis. Participants will: * Be treated with either a low-dose or high-dose of JYP0061. * Undergo efficacy and safety evaluations as stipulated in the trial protocol.

Official title: An Efficacy and Safety Study of JYP0061 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2023-12-27

Completion Date

2026-10-10

Last Updated

2025-03-20

Healthy Volunteers

No

Interventions

DRUG

JYP0061 15 mg

Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.

DRUG

JYP0061 30 mg

articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.

DRUG

Placebo

Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.

Locations (1)

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, China